Loading…
Clinical-stage biotech developing inhaled molgramostim for autoimmune pulmonary alveolar proteinosis, a rare lung disease.
Clinical-stage biotech developing inhaled molgramostim for autoimmune pulmonary alveolar proteinosis, a rare lung disease.
Has no product on sale, so it earns no sales; development is funded by money raised from investors. Its only late-stage drug is aimed at a rare disease, so the company's value depends on regulators approving that one drug and then on selling to a small patient group.
Moat: narrow (IP / patents, regulatory licence). First potential approved therapy for a rare disease with no current approved treatment.
Headquarters: Langhorne, Pennsylvania, US · Employees: 70
Size Savara (SVRA) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $992M, the 2250th largest of 3,117 United States companies the cockpit tracks. Shares closed at $4.83 on 6 Nov 2026.
Performance Over six months the shares fell 7.7%, against -14.1% for the median peer and -1.1% for the United States market (cap-weighted) — 5th highest of 19 in its peer set.
Short interest Short interest is 14.0% of the free float (15 Oct 2026).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$281,000 | -$245,000 | -$275,000 | -$175,000 | -$167,000 |
| EBITDA | -$143M | -$123M | -$103M | -$59.8M | -$38.7M |
| Net income | -$139M | -$119M | -$95.9M | -$54.7M | -$38.1M |
| Free cash flow | -$111M | -$101M | -$89.1M | -$51.4M | -$34.6M |
| Capital expenditure | $280,000 | $22,000 | $25,000 | $296,000 | $9,000 |
| Total debt | $30.4M | $29.9M | $26.8M | $26.7M | $26.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Savara SVRA | $992M | -8% | n/a | n/a | n/a | n/a |
| Insmed INSM | $25.1B | -16% | +240% | -42% | 16.2× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SVRA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | 0.0% | -7.3% | 7th highest of 20 |
| 6-month return | -7.7% | -14.1% | 5th highest of 19 |
| Distance from 52-week high | -31.1% | -28.6% | 10th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Savara SVRA | United States | $992M | -8% | n/a | n/a | n/a | n/a | n/a |
| SSY 2005.HK | Hong Kong | $990M | +10% | -4% | 12% | 2.3× | 2.1% | -0.5% |
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $999M | -15% | -16% | 13% | 3.0× | 8.8% | -6.9% |
| Zhejiang Garden Biopharmaceutical 300401.SZ | China | $983M | -7% | +2% | 24% | 5.5× | 10.2% | +13.4% |
| KPC Pharmaceuticals 600422.SS | China | $1.00B | -7% | -41% | -10% | 1.9× | n/a | n/a |
| MoonLake Immunotherapeutics MLTX | United States | $981M | -32% | n/a | n/a | n/a | n/a | n/a |
| Harrow HROW | United States | $1.01B | -30% | +21% | 2% | 4.4× | 51.8% | +41.0% |
| Jiangsu Yahong Meditech 688176.SS | China | $973M | -12% | +15% | -172% | 17.8× | n/a | n/a |
| Strides Pharma Science STAR.NS | India | $973M | -13% | +11% | 14% | 2.1× | 18.1% | +7.8% |
| Kissei Pharmaceutical 4547.T | Japan | $973M | -16% | +6% | 6% | 1.1× | n/a | n/a |
| Procter & Gamble Health PGHL.NS | India | $971M | +4% | +13% | 31% | 6.3× | 5.5% | +9.3% |
| Oscotec 039200.KS | South Korea | $1.02B | -30% | +233% | 62% | 8.3× | -9.5% | +18.1% |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $1.03B | -11% | -43% | -42% | 5.0× | 11.9% | -13.7% |
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.03B | n/a | n/a | n/a | n/a | n/a | n/a |
| SAWAI 4887.T | Japan | $1.03B | -22% | +11% | 9% | 1.3× | n/a | n/a |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -16% | +7% | 9% | 1.2× | 1.5% | +12.1% |
| Immatics IMTX | United States | $952M | -44% | -65% | -556% | 10.7× | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | China | $948M | -10% | -6% | 3% | 1.0× | -6.8% | -0.7% |
| City Therapeutics CTY | United States | $944M | n/a | +388% | -442% | n/a | n/a | n/a |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -13% | +31% | -7% | 1.8× | -6.4% | -7.7% |
| Hunan Warrant Pharmaceutical 688799.SS | China | $942M | -20% | +5% | 9% | 4.7× | n/a | n/a |